🇺🇸 FDA
Patent

US 7429616

Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds

granted A61PA61P35/00A61P35/02

Quick answer

US patent 7429616 (Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds) held by The Board of Regents of the University of Texas System expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00